Published in Br J Cancer on September 09, 2008
Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochim Biophys Acta (2010) 1.32
PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One (2010) 1.15
Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells. Radiat Oncol (2012) 1.12
Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol (2010) 1.02
Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol (2010) 1.01
In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues. Br J Cancer (2010) 0.94
Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance. Onco Targets Ther (2013) 0.89
Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma. J Transl Med (2013) 0.89
Overexpression of PTK6 (breast tumor kinase) protein--a prognostic factor for long-term breast cancer survival--is not due to gene amplification. Virchows Arch (2009) 0.87
Identification of a Sam68 ribonucleoprotein complex regulated by epidermal growth factor. J Biol Chem (2009) 0.87
Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells. J Biol Chem (2010) 0.86
PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling. PLoS One (2014) 0.83
Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis. J Transl Med (2013) 0.81
Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy. World J Clin Oncol (2014) 0.77
Sam68 functions as a transcriptional coactivator of the p53 tumor suppressor. Nucleic Acids Res (2016) 0.76
The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer. Chin J Cancer (2016) 0.76
Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer. Cancer Res (2016) 0.76
Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis. Oncotarget (2016) 0.75
The p53 status can influence the role of Sam68 in tumorigenesis. Oncotarget (2016) 0.75
PTK6 promotes hepatocellular carcinoma cell proliferation and invasion. Am J Transl Res (2016) 0.75
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol (2003) 4.05
An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature (1994) 3.30
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol (2001) 2.11
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol (2004) 1.88
BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene (1997) 1.77
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res (2007) 1.75
Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene (1994) 1.75
BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res (1999) 1.59
Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. Mol Cell Biol (2000) 1.58
Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res (2002) 1.58
Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem (1996) 1.56
Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res (2005) 1.49
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene (2003) 1.49
Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene (2000) 1.48
Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J Biol Chem (2005) 1.47
Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene (2006) 1.40
The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2. J Biol Chem (2004) 1.36
Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer (2003) 1.35
PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer (2007) 1.34
Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Mol Cell Biol (2006) 1.33
Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas. J Pathol (2005) 1.30
Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res (2007) 1.27
Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene (2003) 1.27
Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem (2004) 1.25
The intracellular tyrosine kinase Brk sensitizes non-transformed cells to inducers of apoptosis. Cell Cycle (2005) 1.18
Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium. Oral Oncol (2004) 1.15
Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat (2003) 1.12
The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges. Anticancer Drugs (2004) 1.10
Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood (2002) 1.07
The RNA binding protein Sam68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity. Oncogene (2004) 1.00
Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest (1990) 0.97
ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J Cell Physiol (2006) 0.96
Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer. Arch Pathol Lab Med (2007) 0.93
Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma. Histopathology (2006) 0.79
E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res (1994) 4.51
Physical properties and quantification of the ECT stimulus: I. Basic principles. Convuls Ther (1994) 4.18
Bovine spongiform encephalopathy: epidemiological studies on the origin. Vet Rec (1991) 3.99
Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature (1993) 3.88
Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer (1996) 3.30
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol (2003) 3.14
Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci U S A (1996) 2.81
Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer (2000) 2.73
A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg (1985) 2.66
Birthweight specific trends in cerebral palsy. Arch Dis Child (1990) 2.56
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer (2003) 2.43
Trends in birth prevalence of cerebral palsy. Arch Dis Child (1987) 2.34
Stereotactic fine-needle biopsy in 2594 mammographically detected non-palpable lesions. Lancet (1989) 2.22
Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer (1999) 2.19
Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology (2006) 2.14
Oestrogen receptors and survival in early breast cancer. Br Med J (Clin Res Ed) (1981) 2.14
Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer (1997) 2.06
Epidemiology of cerebral palsy in England and Scotland, 1984-9. Arch Dis Child Fetal Neonatal Ed (1998) 2.01
Oestrogen receptors and prognosis in early breast cancer. Lancet (1979) 1.83
Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science (1996) 1.82
Sham TMS: intracerebral measurement of the induced electrical field and the induction of motor-evoked potentials. Biol Psychiatry (2001) 1.74
Life expectancy in children with cerebral palsy. BMJ (1994) 1.72
Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett (1999) 1.68
Lipoprotein(a) in cirrhosis. BMJ (1992) 1.63
Metal-responsive elements act as positive modulators of human metallothionein-IIA enhancer activity. Mol Cell Biol (1987) 1.62
The changing epidemiology of cerebral palsy. Arch Dis Child Fetal Neonatal Ed (1996) 1.60
Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol (2000) 1.57
Prevention of tumour cell dissemination in diagnostic needle procedures. Br J Cancer (2010) 1.57
Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene (1999) 1.55
Review and meta-analysis of epidemiological associations between low/moderate doses of ionizing radiation and circulatory disease risks, and their possible mechanisms. Radiat Environ Biophys (2009) 1.55
The effects of electroconvulsive therapy on quantitative electroencephalograms. Relationship to clinical outcome. Arch Gen Psychiatry (1996) 1.53
Collaborative exercise on the use of FISH chromosome painting for retrospective biodosimetry of Mayak nuclear-industrial personnel. Int J Radiat Biol (2001) 1.48
Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer (2006) 1.48
Quantitative EEG during seizures induced by electroconvulsive therapy: relations to treatment modality and clinical features. I. Global analyses. J ECT (2000) 1.44
Recommendations for HER2 testing in the UK. J Clin Pathol (2000) 1.41
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer (2010) 1.38
Effects of birth weight, gestational age, and maternal obstetric history on birth prevalence of cerebral palsy. Arch Dis Child (1987) 1.37
The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer (1991) 1.35
PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer (2007) 1.34
Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol (2002) 1.31
Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat (2003) 1.30
HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol (2012) 1.29
Different brain networks mediate task performance in normal aging and AD: defining compensation. Neurology (2000) 1.28
The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye (Lond) (2006) 1.26
Laminin-5 as a marker of invasiveness in cervical lesions. J Natl Cancer Inst (1999) 1.25
Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer (2008) 1.24
The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer (2005) 1.24
Comparison of established and emerging biodosimetry assays. Radiat Res (2013) 1.23
Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans. Cancer Res (1984) 1.23
Epithelial-myoepithelial duct carcinoma of salivary glands: a follow-up and cytophotometric study of 21 cases. J Oral Pathol Med (1989) 1.23
Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res (1996) 1.23
Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer (2007) 1.22
HER2 testing in the UK: further update to recommendations. J Clin Pathol (2008) 1.22
The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat (2010) 1.21
Prognostic factors for adenoid cystic carcinoma of the head and neck: a retrospective evaluation of 96 cases. J Oral Pathol Med (1990) 1.20
The interactions of the flavivirus envelope proteins: implications for virus entry and release. Arch Virol Suppl (1994) 1.20
Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease. Br J Cancer (1982) 1.19
Computerized quality-of-life screening in an oncology clinic. Cancer Pract (1997) 1.19
Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg (1992) 1.19
A systematic review of epidemiological associations between low and moderate doses of ionizing radiation and late cardiovascular effects, and their possible mechanisms. Radiat Res (2008) 1.19
Mutant EF-Tu increases missense error in vitro. Mol Gen Genet (1986) 1.19
Current "corrected" calcium concept rechallenged. Clin Chem (1977) 1.16
Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline and malignant tumors. Int J Cancer (1997) 1.15
Cerebral palsy and multiple births. Arch Dis Child Fetal Neonatal Ed (1996) 1.15
Advanced-stage cervix cancer: rapid tumour growth rather than late diagnosis. Br J Cancer (2000) 1.14
Proliferative activity and cytochemical properties of nuclear chromatin related to local cell density of epithelial cells. Exp Cell Res (1970) 1.13
Laboratory intercomparison on the γ-H2AX foci assay. Radiat Res (2013) 1.12
Molecular characterization of the MalT-dependent periplasmic alpha-amylase of Escherichia coli encoded by malS. J Biol Chem (1992) 1.12
Cancer proteomics: from identification of novel markers to creation of artifical learning models for tumor classification. Electrophoresis (2000) 1.11
Laboratory intercomparison of gene expression assays. Radiat Res (2013) 1.10
Detection of early neoplastic changes in experimentally induced colorectal cancer using scanning electron microscopy and cell kinetic studies. Gut (1984) 1.09
Mutations that affect meiosis in male mice influence the dynamics of the mid-preleptotene and bouquet stages. Exp Cell Res (2006) 1.09
HER2 and COX2 expression in human prostate cancer. Eur J Cancer (2004) 1.09
Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology (2004) 1.08
Assessment of malignancy potential in so-called interval mammary carcinomas. Breast Cancer Res Treat (1985) 1.08
The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines. Oncogene (1999) 1.08
HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer (2004) 1.08
Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol (2001) 1.07
Tumor cytogenetics revisited: comparative genomic hybridization and spectral karyotyping. J Mol Med (Berl) (1998) 1.07
C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res (1995) 1.06
Linking DNA damage to medulloblastoma tumorigenesis in patched heterozygous knockout mice. Oncogene (2006) 1.06
Expression of tropomyosin isoforms in benign and malignant human breast lesions. Br J Cancer (1996) 1.05
Laboratory intercomparison of the dicentric chromosome analysis assay. Radiat Res (2013) 1.05
Patient acceptance of day surgery. Ann R Coll Surg Engl (1994) 1.04
Sequential proteome alterations during genesis and progression of colon cancer. Cell Mol Life Sci (2004) 1.04
HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer (2003) 1.03
Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int (2002) 1.03
Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC. Oncogene (2008) 1.03
A defective Vkappa A2 allele in Navajos which may play a role in increased susceptibility to haemophilus influenzae type b disease. J Clin Invest (1996) 1.03
Quantitative cytochemical aspects of a combined feulgen-naphthol yellow S staining procedure for the simultaneous determination of nuclear and cytoplasmic proteins and DNA in mammalian cells. Exp Cell Res (1975) 1.02
Deliberate seizure induction with repetitive transcranial magnetic stimulation in nonhuman primates. Arch Gen Psychiatry (2001) 1.02
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis (1999) 1.01
Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer (2006) 1.01
Exon skipping in the E-cadherin gene transcript in metastatic human gastric carcinomas. Hum Mol Genet (1993) 1.01
Estrone and estradiol-17 beta concentration in tissue of the scleractinian coral, Montipora verrucosa. Comp Biochem Physiol A Mol Integr Physiol (1999) 1.00